We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-16.95%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.4B
AUM Growth
-$286M
Cap. Flow
-$9.42M
Cap. Flow %
-0.67%
Top 10 Hldgs %
51.45%
Holding
86
New
13
Increased
27
Reduced
13
Closed
23

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$130M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$56M
3
SRRK icon
Scholar Rock
SRRK
+$50M
4
VERA icon
Vera Therapeutics
VERA
+$45.8M
5
NUVL
Nuvalent
NUVL
+$37.1M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$120M
2
MRK icon
Merck
MRK
+$79.6M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$52.8M
5
SLNO
Soleno Therapeutics
SLNO
+$47.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$157M 11.19%
2,387,720
+1,912,720
+403% +$130M
CYTK icon
2
Cytokinetics
CYTK
$10.8B
$104M 7.44%
2,590,531
+240,531
+10% +$11.1M
INSM icon
3
Insmed
INSM
$22.6B
$82M 5.86%
1,075,000
+175,000
+19% +$13.4M
NUVL
4
DELISTED
Nuvalent
NUVL
$76.2M 5.44%
1,075,000
+475,000
+79% +$37.1M
VERA icon
5
Vera Therapeutics
VERA
$2.39B
$60M 4.29%
2,500,000
+1,425,000
+133% +$45.8M
KALV
6
DELISTED
KalVista Pharmaceuticals
KALV
$54.8M 3.92%
4,751,292
-18,708
-0.4% -$191K
QURE icon
7
uniQure
QURE
$2.52B
$50.8M 3.63%
4,792,572
+1,767,572
+58% +$24.8M
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$8.88B
$50.3M 3.59%
+1,500,000
New +$56M
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.28B
$43.6M 3.11%
1,300,000
+490,000
+60% +$18.6M
SRRK icon
10
Scholar Rock
SRRK
$5.92B
$41.8M 2.98%
+1,300,000
New +$50M
BCAX
11
Bicara Therapeutics
BCAX
$1.77B
$36.1M 2.58%
2,768,975
+2,058,975
+290% +$27.3M
GERN icon
12
Geron
GERN
$930M
$35M 2.5%
22,005,340
+11,005,340
+100% +$26.8M
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$34.9M 2.49%
4,275,000
+925,000
+28% +$8.56M
IMTX icon
14
Immatics
IMTX
$1.19B
$32.4M 2.32%
7,192,700
+917,700
+15% +$4.79M
GPCR icon
15
Structure Therapeutics
GPCR
$3.4B
$31M 2.21%
1,788,990
+63,990
+4% +$1.57M
DNTH icon
16
Dianthus Therapeutics
DNTH
$5.55B
$30.8M 2.2%
1,700,069
+625,069
+58% +$13.8M
SVRA icon
17
Savara
SVRA
$1.09B
$30.5M 2.18%
11,000,000
+225,000
+2% +$621K
TYRA icon
18
Tyra Biosciences
TYRA
$1.84B
$26.8M 1.91%
2,879,829
+1,889,829
+191% +$24.5M
DHR icon
19
Danaher
DHR
$140B
$25.6M 1.83%
+125,000
New +$27.3M
URGN icon
20
UroGen Pharma
URGN
$1.99B
$23.8M 1.7%
2,152,957
+522,957
+32% +$5.58M
ASND icon
21
Ascendis Pharma A/S
ASND
$16.7B
$23.4M 1.67%
150,142
-369,858
-71% -$52.8M
ATXS
22
DELISTED
Astria Therapeutics
ATXS
$22.3M 1.59%
4,180,000
– –
DAWN
23
DELISTED
Day One Biopharmaceuticals
DAWN
$20.6M 1.47%
2,598,127
+1,158,127
+80% +$12.5M
DYN icon
24
Dyne Therapeutics
DYN
$4.28B
$18.8M 1.34%
+1,800,000
New +$25.7M
RARE icon
25
Ultragenyx Pharmaceutical
RARE
$2.56B
$18.1M 1.29%
500,000
-1,000,000
-67% -$41.6M
1
2 3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Vestal Point Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Vestal Point Capital held 86 positions worth $1.4B, down 17% from $1.69B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Vestal Point Capital's Q1 2025 filing shows 13 new, 27 increased, 13 reduced and 23 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 1,500,000 shares worth $50.3M. The largest sale was Jazz Pharmaceuticals, an estimated $120M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Vestal Point Capital's largest Q1 2025 buy was Crinetics Pharmaceuticals: 1,500,000 shares worth $50.3M.
  • Vestal Point Capital added most to Arcellx in Q1 2025, an estimated $130M increase.
  • Vestal Point Capital's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $52.8M.
  • Vestal Point Capital fully exited Jazz Pharmaceuticals in Q1 2025, selling an estimated $120M.
  • Vestal Point Capital's ten largest holdings make up 51% of its $1.4B portfolio in Q1 2025.
  • Vestal Point Capital opened 13 new positions and closed 23 in Q1 2025.
  • Vestal Point Capital's portfolio value fell 17% quarter-over-quarter to $1.4B.

Based on Vestal Point Capital's 13F filing for Q1 2025, filed 15 May 2025.